Patents by Inventor Adel M. Moussa
Adel M. Moussa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10723754Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?,4?-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2?,4?-bridged nucleosides are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.Type: GrantFiled: October 21, 2013Date of Patent: July 28, 2020Assignee: Idenix Pharmaceuticals LLCInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
-
Patent number: 10717758Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: May 16, 2018Date of Patent: July 21, 2020Assignee: IDENIX PHARMACEUTICALS LLCInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, David Dukhan
-
Patent number: 10683321Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4?-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.Type: GrantFiled: December 17, 2014Date of Patent: June 16, 2020Assignee: Idenix Pharmaceuticals LLCInventors: David Dukhan, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 10513534Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: GrantFiled: October 7, 2013Date of Patent: December 24, 2019Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Gilles Gosselin, Christophe Claude Parsy, Francois-Rene Alexandre, Houcine Rahali, Jean-Francois Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 10251903Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).Type: GrantFiled: October 20, 2015Date of Patent: April 9, 2019Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Bryon L. Simmons, Kevin R. Campos, Artis Klapars, Alistair J. Stewart, Benjamin A. Mayes, Peter E. Maligres, Alan Hyde, Steven Mark Silverman, Yong-Li Zhong, Adel M. Moussa, Kenneth Baker, Kara Van Valkenburg
-
Patent number: 10238680Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.Type: GrantFiled: November 30, 2015Date of Patent: March 26, 2019Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Benjamin Alexander Mayes, Adel M. Moussa, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan
-
Patent number: 10231986Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.Type: GrantFiled: September 25, 2015Date of Patent: March 19, 2019Assignee: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Christophe Claude Parsy, Gilles Gosselin, Jean-François Griffon, Guillaume Brandt, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistar James Stewart
-
Publication number: 20180258130Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 16, 2018Publication date: September 13, 2018Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
-
Publication number: 20180162898Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4?-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.Type: ApplicationFiled: December 17, 2014Publication date: June 14, 2018Applicant: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, James Alistair Stewart
-
Publication number: 20170246198Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).Type: ApplicationFiled: October 20, 2015Publication date: August 31, 2017Applicants: IDENIX Pharmaceuticals LLC, Merck Sharp & Dohme Corp.Inventors: Bryon L. SIMMONS, Kevin R. CAMPOS, Artis KLAPARS, Alistair J. STEWART, Benjamin A. MAYES, Peter E. MALIGRES, Alan HYDE, Steven Mark SILVERMAN, Yong-Li ZHONG, Adel M. MOUSSA, Kenneth BAKER, Kara van VALKENBURG
-
Publication number: 20170135990Abstract: Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also provided herein are pharmaceutical compositions comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, method of their preparation, and their use for treating or preventing hepatitis C virus infection.Type: ApplicationFiled: March 4, 2015Publication date: May 18, 2017Applicant: Idenix Pharmaceuticals LLCInventors: Adel M. Moussa, Benjamin Alexander Mayes, Sindhura Ganga
-
Publication number: 20170066779Abstract: Provided herein are crystalline and salt forms of methyl N-{(1R)-2-[(2S)-2-{5-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-3H-benzimidazol-5-yl}thieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl} carbamate, a Flaviviridae, including hepatitis C, virus inhibitor, pharmaceutical compositions comprising the compound, and processes of preparation thereof. Also provided are methods of its use for the treatment of a Flaviviridae, including HCV, infection in a subject in need thereof.Type: ApplicationFiled: March 4, 2015Publication date: March 9, 2017Applicant: IDENIX Pharmaceuticals LLCInventors: Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Publication number: 20170066795Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: March 5, 2015Publication date: March 9, 2017Applicants: IDENIX PHARMACEUTICALS LLC, Merck Sharp & Dohme Corp.Inventors: John Zoltan Sulliva-Bolyai, Benjamin Alexander Mayes, Douglas Lytle Mayers, Xiao-Jian Zhou, Adel M. Moussa, Alistair James Stewart, Sindhura Ganga, Clinton Scott Shultz, Alfred Lee
-
Publication number: 20160280729Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Z1 Z2, Z3, Z4, V, W, X, Y, Ar, R1 and R2 are as described herein.Type: ApplicationFiled: November 19, 2014Publication date: September 29, 2016Applicant: IDENIX PHARMACEUTICALS LLCInventors: Adel M. Moussa, Alistair James Stewart, Benjamin Alexander Mayes
-
Publication number: 20160271162Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-alanine phosphoramidate pronucleotides of 2?-methyl 2?-fluoro guanosine nucleoside which display remarkable efficacy and bioavailability for the treatment of for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; where W and R are as described herein.Type: ApplicationFiled: October 30, 2014Publication date: September 22, 2016Applicant: IDENIX PHARMACUETICALS, LLCInventors: Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 9339541Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: March 3, 2014Date of Patent: May 17, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Cyril B. Dousson, Benjamin Alexander Mayes, David Dukhan, Adel M. Moussa, Alistair James Stewart
-
Publication number: 20160113956Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.Type: ApplicationFiled: September 25, 2015Publication date: April 28, 2016Inventors: David DUKHAN, Christophe Claude PARSY, Gilles GOSSELIN, Jean-François GRIFFON, Guillaume BRANDT, Cyril B. DOUSSON, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 9309275Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.Type: GrantFiled: March 3, 2014Date of Patent: April 12, 2016Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Alistair James Stewart, Adel M. Moussa, Benjamin Alexander Mayes, Francois-Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin
-
Publication number: 20160082030Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.Type: ApplicationFiled: November 30, 2015Publication date: March 24, 2016Inventors: Benjamin Alexander Mayes, Adel M. MOUSSA, Cyril B. DOUSSON, Gilles GOSSELIN, Claire PIERRA, David DUKHAN
-
Publication number: 20160083413Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: ApplicationFiled: October 22, 2015Publication date: March 24, 2016Inventors: Gilles Gosselin, Christophe Claude Parsy, François-René Alexandre, Houcine Rahali, Jean-François Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart, David Dukhan